ATE309224T1 - Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren - Google Patents

Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren

Info

Publication number
ATE309224T1
ATE309224T1 AT00946235T AT00946235T ATE309224T1 AT E309224 T1 ATE309224 T1 AT E309224T1 AT 00946235 T AT00946235 T AT 00946235T AT 00946235 T AT00946235 T AT 00946235T AT E309224 T1 ATE309224 T1 AT E309224T1
Authority
AT
Austria
Prior art keywords
trionene
pyrimidine
metalloproteinase inhibitors
metalloproteinase
inhibitors
Prior art date
Application number
AT00946235T
Other languages
English (en)
Inventor
Julian Blagg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE309224T1 publication Critical patent/ATE309224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00946235T 1999-08-12 2000-08-03 Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren ATE309224T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14854799P 1999-08-12 1999-08-12
PCT/IB2000/001090 WO2001012611A1 (en) 1999-08-12 2000-08-03 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE309224T1 true ATE309224T1 (de) 2005-11-15

Family

ID=22526231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946235T ATE309224T1 (de) 1999-08-12 2000-08-03 Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren

Country Status (41)

Country Link
US (1) US6579982B1 (de)
EP (1) EP1202974B1 (de)
JP (1) JP2003507371A (de)
KR (2) KR20020047119A (de)
CN (1) CN1156454C (de)
AR (1) AR025091A1 (de)
AT (1) ATE309224T1 (de)
AU (1) AU773751B2 (de)
BG (1) BG106406A (de)
BR (1) BR0013081A (de)
CA (1) CA2381551A1 (de)
CO (1) CO5180629A1 (de)
CR (1) CR6565A (de)
CZ (1) CZ2002355A3 (de)
DE (1) DE60023903D1 (de)
EA (1) EA004680B1 (de)
EC (1) ECSP003610A (de)
EE (1) EE200200069A (de)
GE (1) GEP20053424B (de)
GT (1) GT200000137A (de)
HK (1) HK1045995B (de)
HN (1) HN2000000137A (de)
HR (1) HRP20020129A2 (de)
HU (1) HUP0202501A3 (de)
IL (1) IL148035A0 (de)
IS (1) IS6248A (de)
MA (1) MA26812A1 (de)
MX (1) MXPA02001561A (de)
NO (1) NO20020662L (de)
NZ (1) NZ516562A (de)
OA (1) OA12000A (de)
PA (1) PA8498701A1 (de)
PE (1) PE20010491A1 (de)
PL (1) PL353871A1 (de)
SK (1) SK1652002A3 (de)
TN (1) TNSN00169A1 (de)
TR (1) TR200200381T2 (de)
UY (1) UY26285A1 (de)
WO (1) WO2001012611A1 (de)
YU (1) YU6602A (de)
ZA (1) ZA200201070B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
OA12528A (en) * 2000-10-26 2006-06-02 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CA2425283A1 (en) * 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
WO2002064578A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Benzo thiadiazine matrix metalloproteinase inhibitors
JP2004518723A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ピリミジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
MXPA04010545A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
JP2005527598A (ja) * 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
MXPA04010550A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014892A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20150366275A1 (en) * 2014-06-19 2015-12-24 Gyula Cserfoi Wearable Signaling Device
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008827A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
AU746853B2 (en) * 1997-06-21 2002-05-02 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity

Also Published As

Publication number Publication date
AU6010500A (en) 2001-03-13
UY26285A1 (es) 2001-03-16
TNSN00169A1 (fr) 2005-11-10
OA12000A (en) 2006-04-18
WO2001012611A1 (en) 2001-02-22
GT200000137A (es) 2002-02-01
IL148035A0 (en) 2002-09-12
HRP20020129A2 (en) 2004-04-30
HK1045995B (zh) 2004-12-31
CZ2002355A3 (cs) 2002-07-17
JP2003507371A (ja) 2003-02-25
DE60023903D1 (de) 2005-12-15
HN2000000137A (es) 2001-02-02
EA004680B1 (ru) 2004-06-24
MXPA02001561A (es) 2002-07-02
CN1156454C (zh) 2004-07-07
PE20010491A1 (es) 2001-04-25
AR025091A1 (es) 2002-11-06
NO20020662L (no) 2002-04-09
EE200200069A (et) 2003-04-15
CN1368963A (zh) 2002-09-11
BR0013081A (pt) 2002-04-23
ZA200201070B (en) 2003-04-30
CO5180629A1 (es) 2002-07-30
NZ516562A (en) 2003-06-30
AU773751B2 (en) 2004-06-03
PA8498701A1 (es) 2002-08-26
MA26812A1 (fr) 2004-12-20
CR6565A (es) 2004-02-23
NO20020662D0 (no) 2002-02-11
EP1202974A1 (de) 2002-05-08
YU6602A (sh) 2004-11-25
KR20020047119A (ko) 2002-06-21
HUP0202501A3 (en) 2003-02-28
BG106406A (en) 2002-09-30
EA200200058A1 (ru) 2002-06-27
TR200200381T2 (tr) 2002-05-21
HK1045995A1 (en) 2002-12-20
PL353871A1 (en) 2003-12-01
KR20040073608A (ko) 2004-08-19
HUP0202501A2 (hu) 2002-12-28
ECSP003610A (es) 2002-03-25
SK1652002A3 (en) 2002-09-10
EP1202974B1 (de) 2005-11-09
US6579982B1 (en) 2003-06-17
CA2381551A1 (en) 2001-02-22
IS6248A (is) 2002-01-25
GEP20053424B (en) 2005-01-25

Similar Documents

Publication Publication Date Title
DE60023903D1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
NO20031852D0 (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
ATE312613T1 (de) Niedrig dosierte entecavir formulierung und deren verwendung
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60136736D1 (de) Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
DE59908600D1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
ATE273283T1 (de) Diphenylharnstoffderivate und deren verwendung als alpha2/5-ht2c antagonisten
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE300525T1 (de) Uracilverbindungen und deren verwendung
ATE234840T1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv
DE60107603D1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
DE60123458D1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
DE60013191D1 (de) Tensidzusammensetzung und deren Verwendung
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE60036885D1 (de) Succinimidverbindungen und deren verwendung
DE69925866D1 (de) Aussermembranproteine, ihre gene, und deren verwendung
DE60011801D1 (de) Benzoxa- und benzthiazolylsulfamate sowie ihre verwendung als steroid-sulfataseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties